Recent Advances in the Rational Drug Design Based on Multi-target Ligands

Multi-target drugs have gained considerable attention in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance. Single-target drugs, although highly selective, may not necessarily have better efficacy or fewer side effects. Therefore, more attention is being paid to developing drugs that work on multiple targets at the same time, but developing such drugs is a huge challenge for medicinal chemists. Each target must have sufficient activity and have sufficiently characterized pharmacokinetic parameters. Multi-target drugs, which have long been known and effectively used in clinical practice, are briefly discussed in the present article. In addition, in this review, we will discuss the possible applications of multi-target ligands to guide the repositioning of prospective drugs.

Download Full-text

Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design

Cell Reports ◽

10.1016/j.celrep.2020.02.108 ◽

2020 ◽

Vol 30 (12) ◽

pp. 3951-3963.e4

Author(s):

Scott M. Leighow ◽

Chuan Liu ◽

Haider Inam ◽

Boyang Zhao ◽

Justin R. Pritchard

Keyword(s):

Drug Resistance ◽

Drug Design ◽

Design Principles ◽

Rational Drug Design ◽

Multi Scale ◽

Rational Drug

Download Full-text

The relationship between rational drug design and drug side effects

Briefings in Bioinformatics ◽

10.1093/bib/bbr061 ◽

2011 ◽

Vol 13 (3) ◽

pp. 377-382 ◽

Cited By ~ 24

Author(s):

J. Wang ◽

Z.-x. Li ◽

C.-x. Qiu ◽

D. Wang ◽

Q.-h. Cui

Keyword(s):

Side Effects ◽

Drug Design ◽

Rational Drug Design ◽

Drug Side Effects ◽

Rational Drug ◽

The Relationship

Download Full-text

Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance

Cellular and Molecular Life Sciences ◽

10.1007/s00018-006-6009-7 ◽

2006 ◽

Vol 63 (15) ◽

pp. 1706-1724 ◽

Cited By ~ 33

Author(s):

P. D. Yin ◽

D. Das ◽

H. Mitsuya

Keyword(s):

Drug Resistance ◽

Drug Design ◽

Rational Drug Design ◽

Hiv Drug Resistance ◽

Hiv Resistance ◽

Rational Drug

Download Full-text

Type II topoisomerases as targets for rational drug design

Acta Crystallographica Section A Foundations and Advances ◽

10.1107/s2053273314092869 ◽

2014 ◽

Vol 70 (a1) ◽

pp. C713-C713

Author(s):

Ivan Laponogov ◽

Dennis Veselkov ◽

Trishant Umrekar ◽

Isabelle Crevel ◽

Xiao-su Pan ◽

...

Keyword(s):

Drug Resistance ◽

Drug Design ◽

Dna Supercoiling ◽

Rational Drug Design ◽

Human Organism ◽

Type Ii ◽

Double Stranded Dna ◽

Rational Drug ◽

Bacterial Drug Resistance ◽

Anti Cancer

Bacterial drug resistance is a growing and now widely recognised threat and the limited number of new antibacterials developed in the recent years is a serious matter of concern. One of the approaches to combat this growing threat is to investigate the mechanisms of action of currently available antibacterials, as well as studying the way that bacteria are currently developing drug resistance and may potentially in the future develop drug resistance to known remedies. This knowledge should in turn be used in rational drug design and the general development of the appropriate frameworks for combating bacteria, while at the same time keeping the negative side effects of the drugs to the acceptable minimum. This is especially important when both bacteria and humans share similar drug targets, such as is the case for topoisomerases (in humans, the latter are also targeted by anti-cancer drugs). Our main protein targets of interest are type II topoisomerases which are involved in regulation of the DNA supercoiling in both bacteria and eukaryotes and also in decatenation of bacterial daughter chromosomes during cell division. Type II topoisomerases are performing their biological action by binding the double stranded DNA (called G-segment or Gate-DNA), temporarily cleaving it and passing another double stranded DNA (called T-segment) in the ATP-assisted process via the cleavage region thus changing the linking number in steps of12. After that the G-segment is resealed and released. Several drugs were found to be able to disrupt this process ultimately resulting in the cell death (thus having anti-bacterial or anti-cancer action). Here we present our studies of the protein-DNA-drug interactions which are involved in the action of currently clinically used quinolone antibacterials as well as their newly developed alternatives (such as quinazolinediones) in relation to their mechanism of action and already established potential routes for developing drug resistance in bacteria. We present the results for different pathogens (including, but not limited to Streptococcus pneumoniae and Klebsiella pneumoniae) and also compare the configuration of the active site with the one from type II topoisomerases from a human organism.

Download Full-text

Rational Drug Design Approach for Overcoming Drug Resistance: Application to Pyrimethamine Resistance in Malaria

Journal of Medicinal Chemistry ◽

10.1021/jm970845u ◽

1998 ◽

Vol 41 (9) ◽

pp. 1367-1370 ◽

Cited By ~ 49

Author(s):

James H. McKie ◽

Kenneth T. Douglas ◽

Cecil Chan ◽

Simon A. Roser ◽

Robert Yates ◽

...

Keyword(s):

Drug Resistance ◽

Drug Design ◽

Rational Drug Design ◽

Design Approach ◽

Rational Drug

Download Full-text

Applications of Molecular Simulation in the Discovery of Antituberculosis Drugs: A Review

Protein and Peptide Letters ◽

10.2174/0929866526666190620145919 ◽

2019 ◽

Vol 26 (9) ◽

pp. 648-663 ◽

Cited By ~ 3

Author(s):

Jian-Ping Hu ◽

Zhi-Xiang Wu ◽

Tao Xie ◽

Xin-Yu Liu ◽

Xiao Yan ◽

...

Keyword(s):

Drug Resistance ◽

Mycobacterium Tuberculosis ◽

Drug Design ◽

Molecular Simulation ◽

Rational Drug Design ◽

Dynamics Simulation ◽

Simulation Methods ◽

Antituberculosis Drugs ◽

Rational Drug ◽

Low Toxic

:After decades of efforts, tuberculosis has been well controlled in most places. The existing drugs are no longer sufficient for the treatment of drug-resistant Mycobacterium tuberculosis due to significant toxicity and selective pressure, especially for XDR-TB. In order to accelerate the development of high-efficiency, low-toxic antituberculosis drugs, it is particularly important to use Computer Aided Drug Design (CADD) for rational drug design. Here, we systematically reviewed the specific role of molecular simulation in the discovery of new antituberculosis drugs.:The purpose of this review is to overview current applications of molecular simulation methods in the discovery of antituberculosis drugs. Furthermore, the unique advantages of molecular simulation was discussed in revealing the mechanism of drug resistance.:The comprehensive use of different molecular simulation methods will help reveal the mechanism of drug resistance and improve the efficiency of rational drug design.:With the help of molecular simulation methods such as QM/MM method, the mechanisms of biochemical reactions catalyzed by enzymes at atomic level in Mycobacterium tuberculosis has been deeply analyzed. QSAR and virtual screening both accelerate the development of highefficiency, low-toxic potential antituberculosis drugs. Improving the accuracy of existing algorithms and developing more efficient new methods for CADD will always be a hot topic in the future. It is of great value to utilize molecular dynamics simulation to investigate complex systems that cannot be studied in experiments, especially for drug resistance of Mycobacterium tuberculosis.

Download Full-text

Current computer-aided drug design methodologies in discovery of novel drug candidates for neuropsychiatric and inflammatory diseases

Arhiv za farmaciju ◽

10.5937/arhfarm71-32523 ◽

2021 ◽

Vol 71 (4) ◽

pp. 225-256

Author(s):

Milica Radan ◽

Jelena Bošković ◽

Vladimir Dobričić ◽

Olivera Čudina ◽

Katarina Nikolić

Keyword(s):

Drug Discovery ◽

Side Effects ◽

Drug Design ◽

Inflammatory Diseases ◽

Rational Drug Design ◽

Computer Aided Drug Design ◽

Drug Discovery And Development ◽

Rational Drug ◽

Computer Aided ◽

Anti Inflammatory

Drug discovery and development is a very challenging, expensive and time-consuming process. Impressive technological advances in computer sciences and molecular biology have made it possible to use computer-aided drug design (CADD) methods in various stages of the drug discovery and development pipeline. Nowadays, CADD presents an efficacious and indispensable tool, widely used in medicinal chemistry, to lead rational drug design and synthesis of novel compounds. In this article, an overview of commonly used CADD approaches from hit identification to lead optimization was presented. Moreover, different aspects of design of multitarget ligands for neuropsychiatric and anti-inflammatory diseases were summarized. Apparently, designing multi-target directed ligands for treatment of various complex diseases may offer better efficacy, and fewer side effects. Antipsychotics that act through aminergic G protein-coupled receptors (GPCRs), especially Dopamine D2 and serotonin 5-HT2A receptors, are the best option for treatment of various symptoms associated with neuropsychiatric disorders. Furthermore, multi-target directed cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) inhibitors are also a successful approach to aid the discovery of new anti-inflammatory drugs with fewer side effects. Overall, employing CADD approaches in the process of rational drug design provides a great opportunity for future development, allowing rapid identification of compounds with the optimal polypharmacological profile.

Download Full-text

Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem

Drug Discovery Today ◽

10.1016/j.drudis.2012.06.018 ◽

2012 ◽

Vol 17 (19-20) ◽

pp. 1121-1126 ◽

Cited By ~ 38

Author(s):

Ge-Fei Hao ◽

Guang-Fu Yang ◽

Chang-Guo Zhan

Keyword(s):

Drug Resistance ◽

Drug Design ◽

Rational Drug Design ◽

Rational Drug

Download Full-text

Improving the Accuracy of Protein-Ligand Binding Affinity Prediction by Deep Learning Models: Benchmark and Model

10.26434/chemrxiv.9866912 ◽

2019 ◽

Author(s):

Mohammad Rezaei ◽

Yanjun Li ◽

Xiaolin Li ◽

Chenglong Li

Keyword(s):

Deep Learning ◽

Drug Design ◽

Binding Affinity ◽

Benchmark Dataset ◽

Rational Drug Design ◽

Learning Models ◽

Structure Based Drug Design ◽

Binding Affinity Prediction ◽

Affinity Prediction ◽

Rational Drug

Introduction: The ability to discriminate among ligands binding to the same protein target in terms of their relative binding affinity lies at the heart of structure-based drug design. Any improvement in the accuracy and reliability of binding affinity prediction methods decreases the discrepancy between experimental and computational results. Objectives: The primary objectives were to find the most relevant features affecting binding affinity prediction, least use of manual feature engineering, and improving the reliability of binding affinity prediction using efficient deep learning models by tuning the model hyperparameters. Methods: The binding site of target proteins was represented as a grid box around their bound ligand. Both binary and distance-dependent occupancies were examined for how an atom affects its neighbor voxels in this grid. A combination of different features including ANOLEA, ligand elements, and Arpeggio atom types were used to represent the input. An efficient convolutional neural network (CNN) architecture, DeepAtom, was developed, trained and tested on the PDBbind v2016 dataset. Additionally an extended benchmark dataset was compiled to train and evaluate the models. Results: The best DeepAtom model showed an improved accuracy in the binding affinity prediction on PDBbind core subset (Pearson’s R=0.83) and is better than the recent state-of-the-art models in this field. In addition when the DeepAtom model was trained on our proposed benchmark dataset, it yields higher correlation compared to the baseline which confirms the value of our model. Conclusions: The promising results for the predicted binding affinities is expected to pave the way for embedding deep learning models in virtual screening and rational drug design fields.

Download Full-text

Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors

Current Medicinal Chemistry ◽

10.2174/0929867325666180622143548 ◽

2020 ◽

Vol 26 (42) ◽

pp. 7623-7640 ◽

Cited By ~ 1

Author(s):

Cheolhee Kim ◽

Eunae Kim

Keyword(s):

Drug Design ◽

Tyrosine Kinase ◽

Receptor Tyrosine Kinase ◽

Synergistic Effects ◽

Rational Drug Design ◽

Computational Techniques ◽

Biological Targets ◽

Type Iii ◽

Theoretical Approaches ◽

Rational Drug

: Rational drug design is accomplished through the complementary use of structural biology and computational biology of biological macromolecules involved in disease pathology. Most of the known theoretical approaches for drug design are based on knowledge of the biological targets to which the drug binds. This approach can be used to design drug molecules that restore the balance of the signaling pathway by inhibiting or stimulating biological targets by molecular modeling procedures as well as by molecular dynamics simulations. Type III receptor tyrosine kinase affects most of the fundamental cellular processes including cell cycle, cell migration, cell metabolism, and survival, as well as cell proliferation and differentiation. Many inhibitors of successful rational drug design show that some computational techniques can be combined to achieve synergistic effects.

Download Full-text